182 related articles for article (PubMed ID: 17137406)
1. Sunitinib.
Deeks ED; Keating GM
Drugs; 2006; 66(17):2255-66; discussion 2267-8. PubMed ID: 17137406
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
3. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
5. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib.
Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
Schöffski P; Bukowski R; Flodgren P; Ravaud A
Ann Oncol; 2009 May; 20 Suppl 1():i25-i30. PubMed ID: 19430005
[TBL] [Abstract][Full Text] [Related]
11. Expanding the boundaries of clinical practice: building on experience with targeted therapies.
Sternberg CN
Ann Oncol; 2009 May; 20 Suppl 1():i1-6. PubMed ID: 19430002
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in solid tumors.
Gan HK; Seruga B; Knox JJ
Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
[TBL] [Abstract][Full Text] [Related]
13. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.
Boorjian S
Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.
Bond M; Hoyle M; Moxham T; Napier M; Anderson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():69-74. PubMed ID: 19804692
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].
Li XS; Song Y; Gong K; Zhang Q; Yu W; Song G; Zhao Z; Zhang Z; Wang G; Zhou LQ; He ZS; Jin J
Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(5):375-7. PubMed ID: 20450612
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
